Karyopharm Therapeutics
KPTI
KPTI
118 hedge funds and large institutions have $103M invested in Karyopharm Therapeutics in 2023 Q3 according to their latest regulatory filings, with 16 funds opening new positions, 40 increasing their positions, 29 reducing their positions, and 35 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
less ownership
Funds ownership: →
less funds holding
Funds holding: →
29% less capital invested
Capital invested by funds: $145M → $103M (-$42.2M)
54% less first-time investments, than exits
New positions opened: 16 | Existing positions closed: 35
Holders
118
Holding in Top 10
–
Calls
$785K
Puts
$182K
Top Buyers
| 1 | +$2.25M | |
| 2 | +$1.61M | |
| 3 | +$1.41M | |
| 4 |
Morgan Stanley
New York
|
+$834K |
| 5 |
GCP
GSA Capital Partners
London,
United Kingdom
|
+$762K |
Top Sellers
| 1 | -$3.2M | |
| 2 | -$2.06M | |
| 3 | -$1.65M | |
| 4 |
ECM
ExodusPoint Capital Management
New York
|
-$1.32M |
| 5 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
-$1.26M |